(Q30965003)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

review article

1 reference

title

Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

16 February 2020

main subject

0 references

author

Angela Vidal-Jordana

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Jaume Sastre Garriga

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Xavier Montalban

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Alex Rovira

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

5 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

262

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

2617-2626

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26041617%20AND%20SRC:MED&resulttype=core&format=json

Multiple sclerosis--the plaque and its pathogenesis

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

The measurement and clinical relevance of brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Central nervous system-directed effects of FTY720 (fingolimod).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Interferon-beta mechanisms of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Teriflunomide and its mechanism of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Guidelines for using proton MR spectroscopy in multicenter clinical MS studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Clinical impact of early brain atrophy in clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-015-7798-0

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

21 January 2018

1 reference

12 December 2020

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes

1 reference

12 December 2020

Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis

1 reference

12 December 2020

Brain atrophy in natalizumab-treated patients: A 3-year follow-up

1 reference

12 December 2020

Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a

1 reference

12 December 2020